A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors

LESSONS LEARNED. Nivolumab treatment at doses of 3 mg/kg once every 2 weeks (Q2W), 240 mg Q2W, and 360 mg once every 3 weeks was well tolerated in the Chinese population, with no new safety signals identified. Comparison of intensive pharmacokinetic profiles of nivolumab at 3 mg/kg Q2W in Chinese ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yuxiang, Fang, Wenfeng, Zhang, Yang, Yang, Yunpeng, Hong, Shaodong, Zhao, Yuanyuan, Tendolkar, Amol, Chen, Lu, Xu, Dong, Sheng, Jennifer, Zhao, Hongyun, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656473/
https://www.ncbi.nlm.nih.gov/pubmed/31048330
http://dx.doi.org/10.1634/theoncologist.2019-0284

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656473/
https://www.ncbi.nlm.nih.gov/pubmed/31048330
http://dx.doi.org/10.1634/theoncologist.2019-0284

Ejemplares similares